Drug Trial Radar · NCT07531745
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Apr 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
Conditions
- Dravet Syndrome
Interventions
ION337Drug
ION337 will be administered by ITB injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
- Number of Participants With Clinically Significant Change From Baseline in Safety Laboratory ValuesTime frame: Part 1: up to 6 months; Part 2: up to 31 months
- Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
- Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)Time frame: Part 1: up to 6 months; Part 2: up to 31 months
- Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
- Parts 1 and 2: Number of Participants with Change in Columbia Suicidality Severity Rating Scale (C-SSRS)Time frame: Part 1: up to 6 months; Part 2: up to 31 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Michigan Health System
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Duke University Health Systems
Durham, North Carolina · Recruiting
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania · Recruiting
Le Bonheur Children's Hospital
Memphis, Tennessee · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
McGill University Health Center - Research Institute
Montreal, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.